Table 3.

Summary of cefepime pharmacokinetic parameters for patients receiving CVVH

PatientDosing regimenCmax(μg/ml)Cmin(μg/ml)AUC0–24(μg · h/ml)t1/2 (h)V (liter/kg)CLSUFRa (ml/min)CRRT CLbSb
ml/minml/min/kgml/minml/min/kg%CLS
12 g every 24 h61.618.7943.513.70.6438 ± 60.54 ± 0.0819 ± 216 ± 40.23 ± 0.0542 ± 30.92 ± 0.07
22 g every 24 h67.413.51,050.910.20.3644 ± 40.41 ± 0.049 ± 83 ± 20.03 ± 0.028 ± 40.84 ± 0.05
32 g every 24 h86.420.71,258.411.40.3833 ± 40.38 ± 0.0419 ± 417 ± 30.19 ± 0.0429 ± 190.89 ± 0.08
41 g every 12 h44.627.9834.717.00.4328 ± 30.29 ± 0.0315 ± 213 ± 30.13 ± 0.0345 ± 140.81 ± 0.13
52 g every 12 h94.948.01,677.812.20.3835 ± 10.36 ± 0.0117 ± 1214 ± 100.14 ± 0.1039 ± 280.83 ± 0.11
Mean ± SD12.9 ± 2.60.46 ± 0.1436 ± 6c 0.40 ± 0.09c 16 ± 4a 13 ± 4a 0.15 ± 0.06c 40 ± 16c 0.86 ± 0.04c
  • a UFR, ultrafiltration rate.

  • b Values are means ± standard deviations calculated from parameter values determined during each of the four or five postdose sampling intervals for each patient: 1 to 2 h, 2 to 4 h, 4 to 8 h, 8 to 12 h, and 12 to 24 h (except with 12-h dosing interval regimens).

  • c Means ± standard deviations calculated from means of the four or five parameter values determined for each individual patient.